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Purpose
Melanoma is a highly heterogeneous neoplasm, composed of subpopulations of tumor cells
with distinct molecular and biological phenotypes and genotypes. In this study, to determine
the genetic heterogeneity between primary and metastatic melanoma in Korean melanoma
patients, we evaluated several well-known genetic alterations of melanoma. In addition, to
elucidate the clinical relevance of each genetic alteration and heterogeneity between pri-
mary and metastatic lesions, clinical features and patient outcome were collected. 
Materials and Methods
In addition to clinical data, BRAF, NRAS, GNAQ/11 mutation and KIT amplification data was
acquired from an archived primary Korean melanoma cohort (KMC) of 188 patients. Among
these patients, 43 patients were included for investigation of tumor heterogeneity between
primary melanoma and its corresponding metastatic lesions.
Results
Overall incidence of genetic aberrations of the primary melanomas in KMC was 17.6% of
BRAF V600, 12.6% of NRAS mutation, and 28.6% of KIT amplification. GNAQ/11 mutation
was seen in 66.6% of the uveal melanoma patients. Patients with BRAF mutation were 
associated with advanced stage and correlated to poor prognosis (p < 0.01). Among 43 
patients, 55.8% showed heterogeneity between primary and metastatic lesion. The fre-
quency of BRAF mutation and KIT amplification significantly increased in the metastatic 
lesions compared to primary melanomas. GNAQ/11 mutation showed 100% homogeneity
in uveal melanoma patients.  
Conclusion
Our data demonstrated heterogeneity between primary melanomas and corresponding
metastatic lesions for BRAF, NRAS mutation and KIT amplification. However, GNAQ/11
mutation was genetically homogeneous between primary and metastatic melanoma lesions
in uveal melanoma.
Key words
Melanoma, Heterogeneity, BRAF, KIT, NRAS
Si-Hyung Lee, MD, PhD1
Jee Eun Kim, MD1
Hong Sun Jang, MD1
Kyu Hyun Park2
Byung Ho Oh, MD, PhD1
Sang Joon Shin, MD, PhD2,3
Kee Yang Chung, MD, PhD1,4
Mi Ryung Roh, MD, PhD1
Sun Young Rha, MD, PhD2,3,4
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
Correspondence: Mi Ryung Roh, MD, PhD
Department of Dermatology, Gangnam 
Severance Hospital, Cutaneous Biology 
Research Institute, Yonsei University College of
Medicine, 211 Eonju-ro, Gangnam-gu, 
Seoul 06273, Korea
Tel: 82-2-2019-3360 
Fax: 82-2-2019-4881 
E-mail: karenroh@yuhs.ac
Co-correspondence: Sun Young Rha, MD, PhD
Division of Medical Oncology, Department of
Internal Medicine, Songdang Institute 
for Cancer Research, Yonsei Cancer Center,
Yonsei University College of Medicine, 
50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
Tel: 82-2-2228-8130 
Fax: 82-2-393-3652 
E-mail: rha7655@yuhs.ac 
Received  November 9, 2017
Accepted  January 7, 2018
Published Online  January 22, 2018
1Department of Dermatology, 
Cutaneous Biology Research Institute, 
Yonsei University College of Medicine, Seoul,
2Songdang Institute for Cancer Research, 
Yonsei Cancer Center, Yonsei University 
College of Medicine, Seoul, 3Division of 
Medical Oncology, Department of Internal
Medicine, Yonsei University College of 
Medicine, Seoul, 4Brain Korea 21 Project for
Medical Science, Seoul, Korea
VOLUME 50 NUMBER 4 OCTOBER 2018  1379
Introduction
Melanoma has one of the highest somatic mutational bur-
dens among solid malignancies [1]. In the last decade, a num-
ber of important genetic alterations have been identified
during various stages of melanoma progression leading to a
better understanding and molecular classification of the dis-
ease [2]. Unlike the older histological classification, molecular
approaches define melanoma as a more heterogeneous and
rather complex neoplasm [3]. In 2015, The Cancer Genome
Atlas (TCGA) program described the landscape of genomic
alterations in cutaneous melanoma in which established a
framework for genomic classification into four subtypes:
BRAF subtype, RAS subtype, NF1 subtype, and triple wild-
type (RAF, RAS, and NF1 wild-type) melanomas [4]. This
classification may guide clinical decision-making for targeted
therapy such as BRAF inhibitor or tyrosine kinase inhibitor
[5], and also offers insights to further personalized therapy. 
Like other malignancies, melanoma is a highly heteroge-
neous neoplasm, composed of subpopulations of tumor cells
with distinct molecular and biological phenotypes [6]. More-
over, genotypic and phenotypic analyses of metastatic
melanoma cells have revealed that the tumors are more het-
erogeneous than the primary lesions [7]. In this study, we 
investigated the mutation status of primary and metastatic
melanomas in Korean patients, and their association with
clinical features and impact on the outcome of melanoma 
patients. 
Materials and Methods
1. Patients
This study included 188 melanoma patients, diagnosed
during January 2005 to January 2012, at Yonsei University
College of Medicine, Severance Hospital and Yonsei Cancer
Hospital in Seoul, Korea (Fig. 1). Among the 188 patients
with primary tumors, 43 patients had lymph nodes or distant
metastatic lesions also. Clinical data including age, sex,
tumor-node-metastases (TNM) stage, tumor thickness (Bres-
low), ulceration, and survival (follow-up persisted until the
missing of follow-up or the death of patients) were collected.
The staging was determined according to the American Joint
Committee on Cancer (AJCC) guidelines for melanoma at the
time of diagnosis.  
2. DNA preparation and mutation analyses
Formalin-fixed, paraffin-embedded tissue blocks were 
retrieved and confirmed as malignant melanoma reviewed
by two independent pathologists. Tumor-rich areas (> 80%)
were extracted from five paraffin sections of 10-µm thickness
containing a representative portion of each tumor block,
using the QIAamp DNA FFPE Tissue Kit (Qiagen, Hilden,
Germany). To detect hotspot mutations, we amplified exons
15 (codon 600) of the BRAF gene, exons 1, 2 (codon 12, 13,
and 61) of NRAS gene, and exons 4, 5 (codon 183 and 209) of
GNAQ/11 gene by polymerase chain reaction (PCR). The
Patients of non-CSD, CSD, acral, mucosal, UP type (n=174)
Patients with metastasis (n=38)
  Metachronous metastasis (n=26)
  Synchronous metastasis (n=12)
Patients of uveal type (n=14)
Enrolled 188 patients
  Primary tumor sample only (n=145)
  Primary and LN samples (n=16)
  Primary and distant metastasis samples (n=20)
  Primary and LN and distant metastasis samples (n=7)
BRAF, NRAS mutation by pyrosequencing (n=159)
KIT amplification by real-time PCR assay (n=161)
Patients with metastasis (n=5)
(all metachronous metastasis)
GNAQ/11 mutation by 
pyrosequencing (n=12)
Fig. 1. Study overview. LN, lymph node; CSD, chronic sun-induced damage; UP, unknown primary; PCR, polymerase chain
reaction.
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primer sequences are listed in S1 Table. GNAQ/11 gene 
mutation was only detected in uveal melanoma samples. We
performed pyrosequencing using a PyroMark Q24 (Qiagen,
Germantown, MD) at room temperature with PyroMark
Gold Q24 Reagents (Qiagen) following the manufacturer’s
instructions. Sequencing analysis was performed using 
PyroMark Q24 software ver. 1.0.10 (Qiagen). 
3. Real-time PCR assay for KIT copy number
KIT copy number was assessed by quantitative real-time
PCR using glyceraldehydes-3-phophate dehydrogenase
(GAPDH) as a control gene (The KIT exon 17 primers and
GAPDH primers are listed in S1 Table). PCR reactions were
done by QuantiTect SYBR Green PCR Kit (Qiagen), with a 
20 µL total volume and 100 ng genomic DNA by Rotor-gene
2000 Real-Time Cycler (Corbett Research, Mortlake, Aus-
tralia). The PCR condition was 1 cycle of 95°C for 15 minutes,
followed by 40 cycles of 95°C for 20 seconds, 50°C for 30 sec-
onds, and 72°C for 45 seconds. Relative copy numbers were
calculated by the Ct method, where Ct is the threshold
cycle for amplification. For each sample, Ct for KIT versus
GAPDH was calculated as Ct=Ct (KIT)–Ct (GAPDH). The
Ct value for each experimental test sample was calibrated
to a reference pool of human genomic DNA (Promega, Madi-
son, WI), using the formula Ct=Ct (test sample)–Ct (ref-
erence pool). Relative DNA copy number was calculated
using the formula 2-Ct.  
4. Statistical analysis
All the statistical analyses were performed using SPSS ver.
18.0 software (SPSS Inc., Chicago, IL) and MedCalc ver. 12.7.4.
Categorical data are described using frequencies and percent-
ages. Continuous data such as age are described using
mean±standard deviations or median (range) for normally
distributed data. Chi-square test or Fisher exact test was used
to differentiate the rates of different groups, and differences
in measurement data of two groups were evaluated by 
unpaired t test or Mann-Whitney test. Survival curves were
established using the Kaplan-Meier method and compared
by the log-rank test. All statistical analyses were two-sided,
and significance was assigned at p < 0.05.
5. Ethical statement
This study protocol was approved by the Institutional 
Review Board of Severance Hospital (4-2012-0165) and was
conducted according to the Declaration of Helsinki Princi-
ples. Written informed consent was obtained from all 
patients.
Results
1. Patients and tumor tissue samples
In a total of 188 melanoma patients, the median age was
60 (range, 18 to 89 years) and the sex (male:female) ratio was
1:1.1. The most common subtype was acral type (n=89,
47.3%) followed by nonchronic sun-induced damage (CSD)
type (n=32, 17%) and mucosal type (n=31, 16.5%). CSD type
consisted of 18 patients (9.6%) and 14 patients (7.5%) had
uveal type, while four patients (2.1%) had the tumors of 
unknown primary origin (UP) (Table 1). The UP was diag-
nosed in patients who had initial presentation of melanoma
in the lymph nodes, or subcutaneous tissue with no known
primary site. Of the total patients, 62.8% (n=118) were local-
ized tumors (stages I and II) and 27.2% (n=70) were advan-
ced tumors (stages III and IV). CSD and uveal type tend to
Table 1.  Clinical characteristics of enrolled melanoma patients
Clinicopathological factor Acral Mucosal CSD Non-CSD Uveal UP Total
No. of patients (%) 89 (47.3) 31 (16.5) 18 (9.6) 32 (17) 14 (7.5) 4 (2.1) 188 (100)
Age, median (range, yr) 62 (18-89) 62 (35-82) 60 (39-83) 52 (25-81) 56 (29-75) 47 (37-65) 60 (18-89)
Sex (male:female) 39:50 16:15 12:6 17:15 6:8 1:3 91:97
Stage, n (%)a)
I 30 (33.7) 5 (16.2) 5 (27.8) 13 (40.6) 1 (7.1) 0 ( 54 (28.8)
II 33 (37.0) 9 (29.0) 9 (50.0) 5 (15.6) 8 (57.1) 0 ( 64 (34.0)
III 18 (20.3) 9 (29.0) 2 (11.1) 8 (25.0) 2 (14.4) 2 (50.0) 41 (21.8)
IV 8 (9.0) 8 (25.8) 2 (11.1) 6 (18.8) 3 (21.4) 2 (50.0) 29 (15.4)
CSD, chronic sun-induced damage; UP, unknown primary. a)The staging was determined according to the American Joint
Committee on Cancer guidelines for melanoma at the time of diagnosis.
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have more localized tumors than the other types (77.8% and
64.2%) while mucosal type was more likely to have the 
advanced tumors (54.8%) (Table 1).  
2. Mutation types and frequencies of melanoma
Recent study of genetic alterations in 333 cutaneous
melanomas showed that mutations in BRAF V600 and NRAS
Q61 were found in 46% and 24%, respectively. Although
other genes, including NF1, HRAS, and NRAS, were highly
mutated in cutaneous melanoma, there are no specific hot
spots, which are frequently mutated as BRAF V600 and
NRAS Q61, in these genes [4]. According to a previous study,
KIT amplification was found in 40% of acral melanoma and
31% of mucosal melanoma in Korea [8]. Since our cohort
mainly comprised acral (47.3%) and mucosal (16.5%) mela-
noma, we evaluated genetic status of BRAF (V600) and NRAS
(G12, G13, and Q61), as well as KIT amplification for cuta-
neous melanoma in study. However, uveal melanoma is fre-
quently associated with GNAQ/11 mutations and lacks BRAF
mutation, NRAS mutation and KIT amplification [9,10].
Therefore, we sequenced GNAQ/11 (R183 and Q209) only for
uveal melanoma in this study.
The overall incidence of somatic mutations within the
BRAF V600 gene was 17.6%, NRAS 12.6%, and KIT amplifi-
cation 28.6% in primary melanoma samples. BRAF and NRAS
Table 2.  Genetic alteration status of primary melanoma tissues
Subtype BRAF mutation NRAS mutation KIT amplification GNAQ/11 mutationV600 Q61 and G12-13 R183 and Q209
Non-CSD (n=32) 13/31 (41.9) 2/31 (6.45) 3/32 (9.3) -
CSD (n=18) 4/18 (22.2) 1/18 (5.5) 4/18 (22.2) -
Acral (n=89) 9/82 (10.9) 13/82 (15.8) 29/81 (35.8) -
Mucosal (n=31) 2/26 (7.7) 3/26 (11.5) 8/28 (28.6) -
Uveal (n=14) - - - 8/12 (66.6)
Unknown primary (n=4) 0/2 (0) 1/2 (50) 2/2 (100) -
Total (n=188) 28/159 (17.6) 20/159 (12.6) 46/161 (28.6) 8/12 (66.6)
Values are presented as number (%). CSD, chronic sun-induced damage.
Clinicopathologic
BRAF genotype NRAS genotype KIT genotype
feature Mutation Wild type p-value Mutation Wild type p-value Amplification Normal p-value(n=28) (n=80) (n=20) (n=80) (n=46) (n=78)
Age, median (range, yr) 54 (30-89) 60 (30-87) < 0.01 56 (25-85) 62 (30-87) 0.36 58 (35-81) 62 (30-87) 0.39
Sex
Male 15 (53.6) 35 (43.7) 0.37 9 (45.0) 35 (43.7) 0.92 28 (60.9) 35 (44.9) 0.09
Female 13 (46.4) 45 (56.3) 11 (55.0) 45 (56.3) 18 (39.1) 43 (55.1)
Stage
I 4 (14.3) 31 (38.8) < 0.01 5 (25.0) 31 (38.8) 0.12 12 (26.1) 29 (37.2) 0.33
II 5 (17.9) 24 (30.0) 9 (45.0) 24 (30.0) 20 (43.5) 25 (32.1)
III 10 (35.7) 19 (23.8) 2 (10.0) 19 (23.8) 8 (17.4) 18 (23.1)
IV 9 (32.1) 6 (7.5) 4 (20.0) 6 (7.5) 6 (13.0) 6 (7.7)
Subtype
Non-CSD 13 (46.3) 15 (18.8) 0.05 2 (10.0) 15 (18.8) 0.49 3 (6.5) 15 (19.2) 0.07
CSD 4 (14.3) 10 (12.5) 1 (5.0) 10 (12.5) 4 (8.7) 10 (12.8)
Acral 9 (32.1) 40 (50.0) 13 (65.0) 40 (50.0) 29 (63.0) 37 (47.4)
Mucosal 2 (7.1) 14 (17.5) 3 (15.0) 14 (17.5) 8 (17.4) 16 (20.5)
UP 0 ( 1 (1.3) 1 (5.0) 1 (1.3) 2 (4.3) 0 (
Table 3. Correlation of BRAF, NRAS, and c-KIT status to clinical features of melanoma
Values are presented as number (%) unless otherwise indicated. CSD, chronic sun-induced damage; UP, unknown primary.
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Fig. 2.  Overall survivals of melanoma patients in relation to genetic aberrations. (A) Overall survival in relation to BRAF
mutation. (B) Overall survival in relation to NRAS mutation. (C) Overall survival in relation to KIT amplification. (D) Overall
survival in relation to BRAF mutation in stage 1 and 2 patients. (E) Overall survival in relation to BRAF mutation in stage 3
and 4 patients.
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mutations were mutually exclusive as expected. GNAQ/11
mutation was found in 66.6% of the uveal type (Table 2).
Compared to other subtypes, non-CSD type and acral type
were highly associated with BRAF mutation (41.9%) and KIT
amplification (35.8%), respectively. The BRAF V600E muta-
tion was the most common genetic alteration in this study
(n=27). BRAF V600K mutation was found in only one patient
who was CSD type. 
3. Association of BRAF, NRAS mutations, and KIT ampli-
fication to the clinical features 
In this study, patients with BRAF mutation were signifi-
cantly younger (median age, 54 years) than those with wild-
type BRAF (median age, 60 years) (p < 0.01) (Table 3). Also
advanced tumors in stages III and IV (67.8%) were more sig-
nificantly noticed in patients with BRAF mutation whereas
patients with wild-type BRAF were more in stage I and II
(68.8%). No such tendency was seen in patients with NRAS
mutation or KIT amplification (Table 3).  
4. Prognostic significance of BRAF, NRAS mutations and
KIT amplification with overall survival of melanoma 
We observed that the median survival time for 28 patients
with BRAF mutation (22 months; range, 2 to 158 months) was
significantly shorter than that of 80 patients with wild-type
patients (39 months; range, 4 to 204 months; p < 0.001) (Fig. 2).
To exclude the effect of targeted therapy, including anti-
BRAF treatment, on survival of melanoma patients, patient
treated with targeted therapy was not included in this study.
However, NRAS mutation or KIT amplification did not show
any significant effect on the survival of melanoma patients.
Interestingly, the effect of the BRAF mutation was much
stronger in the patients with localized stage tumors (stage I
and II) rather than patients with regional or metastasized 
tumors (stage III and IV) (Fig. 2).
By Cox multivariate analysis, BRAF mutation was found
to be an independent prognostic factor with the hazard ratio
of 2.258 (p=0.029; 95% confidence interval, 1.08 to 4.69) 
(Table 4). Among the subtypes, mucosal type was shown to
be a poor prognostic factor (p=0.001) as well as increased
stage (p < 0.001), whereas female sex was seen to be a favor-
able prognostic factor (p=0.006) (Table 4). 
5. Comparison of mutation status between primary mela-
noma and corresponding metastatic lesion and its influ-
ence on the outcome of melanoma patients 
Among the 188 melanoma patients, 43 patients had pri-
mary melanoma and its corresponding metastatic lesions
available for the study. Sixteen patients had lymph node
metastasis only, 20 patients had distant metastasis only, and
seven patients had both lymph node and distant metastases.
Among the 43 patients, 55.8% (n=24) showed discordance in
the mutational status between the primary and the corre-
Table 4.  Cox proportional hazard ratios for clinical features and genetic aberrations for overall survival
HR 95% CI p-value
Type
Non-CSD 1.000 Reference 0.006
Acral 1.730 0.78-3.83 0.177
Mucosal 4.691 1.89-11.64 0.001
CSD 2.301 0.83-6.36 0.108
UP 1.378 0.25-7.34 0.707
Sex
Male 1.000 Reference
Female 0.479 0.28-0.81 0.006
Age 1.013 0.99-1.03 0.221
Stage
1, 2 1.000 Reference
3, 4 4.901 2.80-8.56 0.000
Mutation
WT 1.000 Reference 0.127
BRAF 2.258 1.08-4.69 0.029
NRAS 1.344 0.58-3.09 0.488
KIT 1.649 0.83-3.25 0.148
HR, hazard ratio; CI, confidence interval; CSD, chronic sun-induced damage; UP, unknown primary; WT, wild type.
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sponding metastatic lesion suggesting tumor heterogeneity
(S2 Table). In uveal melanoma, 100% concordance was seen
between the primary and corresponding metastatic tumors
(Table 5, S3 Table).
The discordance between the paired tumors did not show
significant association with age, sex, subtype, stage or type
of metastasis (S2 Table). When the metastasis was found at
the time of diagnosis of the primary tumor, it was designated
as a “synchronous” metastasis, and when the metastasis was
found after the initial diagnosis, it was designated as a
“metachronous” metastasis. Thirty-one patients had meta-
chronous metastasis, while 12 patients had synchronous
metastasis. Among the 12 patients with synchronous metas-
tasis, most of the metastasis was detected in the lymph
nodes, except for the two patients whose metastases were 
observed in esophagus and brain. Among the 31 patients
with metachronous metastasis, 15 patients did not receive
any systemic therapy until the metastasis was found (The 
patient characteristics with metastatic tumors are listed in S3
and S4 Table).
In the 31 metachronous metastatic tumors, the frequency
of BRAF mutation and KIT amplification increased in
metastatic tumors compared to its corresponding primary
tumor. The increase of such genetic aberrations at metastatic
lesion was similar in both lymph node metastasis and distant
metastasis (Table 5). Although survival curve suggested poor
survival rate in patient with genetic heterogeneity between
primary tumor and metastatic tumor, especially distant
metastasis, 5-year survival was not statistically different 
between the patient groups (Fig. 3). 
Discussion
Metastatic melanoma is often challenging to treat as 
patients often exhibit drug resistance and experience tumor
recurrence [11]. Resistance of tumors to drug therapy is at
least partially explained by tumor heterogeneity, or the exis-
tence of multiple subclones of tumor cells with varying phe-
notype [12]. In melanoma, the concept of tumor hetero-
geneity was described as early as 1820 when a dissected
melanoma metastasis was discovered to comprise of sections
of different regions in primary melanoma [7]. Thus, this
study aimed to identify the genetic heterogeneity within a
set of well-known genetic alterations including BRAF V600,
NRAS, and GNAQ/11 mutations, and KIT amplification in
188 Korean melanoma patients and its association with clin-
ical features and impact on survival.
The overall incidence of somatic mutations within the
BRAF V600 and NRAS genes were 17.6% and 12.6%, respec-
tively, and KIT amplification was seen in 28.6%. GNAQ/11
mutation in the uveal type was found in 66.6%. Comparing
with the Caucasian data, the frequency of NRAS mutation
were less in our study especially in non-CSD type and CSD
type (6.45% and 5.5%, respectively) [13]. This finding sug-
gests the existence of ethnic difference in molecular patho-
genesis of melanoma, even in same subtype. In addition,
there was a pronounced discrepancy in the proportion of
melanoma subtypes where the acral and mucosal types were
more common compared to Caucasian data [14]. This finding
is consistent with nationwide study investigating the inci-
dence of melanoma in Korea [15]. 
Due to its aggressive progression, there has been continu-
ous effort to find out the prognostic factors of melanoma [16].
Until now, the single most important prognostic factor for
Table 5.  Genetic aberration status in 31 patients with metachronous metastatic tumors 
Mutation in Mutation in distant BRAF mutation NRAS mutation KIT amplification GNAQ/11
primary tumor metastatic tumor (n=21) (n=21) (n=21) mutation (n=5)
Concordance (–) (–) 17 (81.0) 16 (76.2) 6 (28.6) 3 (60)
(+) (+) 0 ( 2 (9.5) 5 (23.8) 2 (40)
Discordance (–) (+) 4 (19.0) 2 (9.5) 6 (28.6) 0 (
(+) (–) 0 ( 1 (4.8) 4 (19.0) 0 (
Mutation in Mutation in metastatic  BRAF mutation NRAS mutation KIT amplification GNAQ/11
primary tumor lymph node (n=12) (n=12) (n=12) mutation (n=1)
Concordance (–) (–) 9 (75.0) 11 (91.7) 6 (50.0) 1 (100)
(+) (+) 1 (8.3) 0 ( 2 (16.7) 0 (
Discordance (–) (+) 2 (16.7) 0 ( 3 (25.0) 0 (
(+) (–) 0 ( 1 (8.3) 1 (8.3) 0 (
Values are presented as number (%).
1384 CANCER  RESEARCH  AND  TREATMENT
Cancer Res Treat. 2018;50(4):1378-1387
the survival in localized melanoma has been the tumor thick-
ness [17]. Activating mutations of the BRAF oncogene have
been reported in 33% to 47% of primary melanomas and 41%
to 55% of metastatic melanoma [18]. The BRAF mutation con-
stitutively activates BRAF and its downstream signaling of
the mitogen-activated protein kinase pathway promoting
proliferation, survival and spreading of tumor cells [19]. 
Although prognostic role of BRAF mutation in melanoma
progression is still controversial [20,21], Long et al. [18] found
that BRAF mutation associated with several features of high-
risk melanoma, including earlier age of onset and shortened
survival. In this study, although patients with BRAF muta-
tion were in advanced stage at the time of diagnosis com-
pared to BRAF wild-type patients, multivariate analysis
revealed that BRAF mutation can also act as an independent
prognostic factor, especially in the early stage melanomas
(stage 1 and 2). Also, patients with BRAF mutation were
younger compared to the BRAF wild-type patients which is
Fig. 3.  Comparison of survival in melanoma patients according to genetic heterogeneity. (A) 5-Year survival according to
genetic concordancy. (B) 5-Year survival according to discordance in metastatic sites. (C) 5-Year survival according to syn-
chronous and metachronous discordance. N, lymph node metastasis; M, distant metastasis; Syn, synchronous; Meta,
metachronous.
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consistent with previous reports [22,23]. 
During tumor progression, subclones frequently arise,
which may result in differences in the proportion and pattern
of specific aberrations between the primary and the metasta-
tic or recurrent tumors that originate from it [24]. In our
study, among the 43 patients with corresponding metastatic
lesions, 55.8% of the patients showed discordance in the 
mutational status suggesting tumor heterogeneity. However,
in our study, tumor heterogeneity did not show any associ-
ation with clinical features. Although survival curve sug-
gested negative effect of tumor heterogeneity on patient
survival, there is no statistical difference in 5-year survival
between the patients with genetic heterogeneity and homo-
geneity. Further study with a large sample size is necessary
to conclude the effect of tumor heterogeneity on patient sur-
vival.
The frequency of BRAF mutation increased significantly in
metastatic lesions compared to primary lesions. Our results
are contrary to previous data indicating that BRAF mutations
occur early in the development of melanoma and the inci-
dence may not vary significantly during tumor progression
[25,26]. However, sequential increase of BRAF mutation rate
was reported in a subset of melanomas during progression
of the disease [27-29]. Together, it is likely that BRAF muta-
tions is not merely initial event in melanomagenesis but has
a role in progression of melanoma.
In uveal melanoma patients, 100% concordance in muta-
tion status between primary and metastatic tumors was 
observed. GNAQ and GNA11 mutations are known to occur
in majority of uveal melanoma patients and are considered
to occur early in uveal melanoma development [9]. Interest-
ingly, several studies on uveal melanoma metastases describe
that most metastases reflect the primary tumor [9] which
may explain our results. However, further studies are 
required to clarify this prediction. 
In conclusion, our study revealed that BRAF mutation was
an independent prognostic factor of poor survival. Also, our
data demonstrated tumor heterogeneity between primary
melanomas and corresponding metastatic lesions for BRAF,
NRAS mutations and KIT amplification, and genetic homo-
geneity in uveal melanoma for GNAQ/11. However, tumor
heterogeneity did not show any significant association with
clinical features and also had no significant impact on sur-
vival of the patients. 
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